NaDeJ (National Deescalation Study One)

Prior treatment

• Previous allergic reaction to cisplatin
• Previous radiotherapy in the head and neck area to overlap the irradiated volume

Other illness

• Hepatic insufficiency with clinical jaundice and impaired coagulation
• Active AIDS disease, but the protocol does not require HIV testing
• Patients with invasive malignancy (except non-melanoma skin cancer) and a history of tumor diagnosis less than 3 years
• Unstable angina or congestive heart failure requiring hospitalization for the last 6 months
• Transmural myocardial infarction last 6 months
• Active infection requiring i.v. antibiotics at the time of registration
• Chronic obstructive bronchoplumonal disease with exacerbation or other respiratory disease requiring hospitalization or postponement of study treatment within 30 days of enrollment

Other

• Tumor in the oral cavity or in nasopharynx or in the hypopharynx or larynx if the p16 is also positive
• Pregnancy
• Tumor of unknown origin (p16 positivity too)
• Simultaneous tumors

• Oropharyngeal squamous cell carcinoma
• Neutrophils ≥ 1,5 x 10x9/l
• Adequate renal functions enable one-week therapy of cisplatina
• Bilirubin, AST or ALT 3x upper limit of norm
• Negative pregnancy test
• Signed informed consent
• Slovak language
• Positivity of p16 by imunohistochemistry
• Clinical stage T1-T2, N1-N2c or T3, N2-N2c, UICC 8th edition without distant metastases
• The lifetime cumulative history of smoking cannot exceed 20 packages / years
• WHO status 0-1
• Age ≥ 18 years
• Both genders
• Hemoglobin ≥ 10 g/l
• Platelets ≥1 00x 10x9/l